Landmark Wealth Management (New York)’s Pfizer PFE Stock Holding History

Landmark Wealth Management (New York)’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$754K	Hold	31,328	–	–	0.18%	89
2026 Q1	$880K	Buy	+31,328	New	+$834K	0.24%	78

Other funds holding PFE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Landmark Wealth Management (New York)'s PFE Position: Q2 2026 in Review

Landmark Wealth Management (New York) held its Pfizer (PFE) position steady in Q2 2026 at 31,328 shares worth $754K. The position accounts for 0.18% of the portfolio, ranked #89.

Landmark Wealth Management (New York) first reported a position in PFE in Q1 2026 and has held it in 2 quarters since. The position peaked at $880K in Q1 2026. 2,841 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

Landmark Wealth Management (New York) held 31,328 shares of Pfizer worth $754K as of Q2 2026.
Landmark Wealth Management (New York) left its Pfizer share count unchanged in Q2 2026.
Pfizer made up 0.18% of Landmark Wealth Management (New York)'s portfolio in Q2 2026, its #89 holding.
Landmark Wealth Management (New York) first reported a position in Pfizer in Q1 2026 and has held it in 2 quarters since.
Landmark Wealth Management (New York)'s Pfizer position peaked at $880K in Q1 2026.
2,841 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Landmark Wealth Management (New York)'s 13F filing for Q2 2026, filed 10 Aug 2026.